Search results for "apparato respiratorio"

showing 10 items of 517 documents

Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics

2016

BACKGROUND: In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with moderate asthma, higher baseline levels of serum periostin are associated with a greater risk of exacerbation. METHODS: Fifteen outpatients with moderate allergic asthma were recruited. Serum concentrations of periostin were assessed (ELISA) at baseline, and the frequency of asthma exacerbations was recorded during a one-year follow-up. RESULTS: Patients (M/F: 10/5, mean age of 47.6 ± 11.0 years) had mean ACQ score of 5.5 ± 4.2 and FEV1%pre…

Allergymedicine.medical_specialtyExacerbationSerum biomarkerPeriostinSettore MED/10 - Malattie Dell'Apparato RespiratorioBiochemistryAllergic inflammation03 medical and health sciences0302 clinical medicineInternal medicinemedicineAsthmatic patient030212 general & internal medicineAirway inflammation; Asthma; Exacerbation; Periostin; Serum biomarkerAsthmabusiness.industryResearchOrganic ChemistryExacerbationmedicine.diseaseSerum biomarker Asthma Periostin Exacerbation Airway inflammationAsthmaPeriostin030228 respiratory systemImmunologyBiomarker (medicine)businessAirwayAirway inflammation
researchProduct

Sleep apnoea and systemic hypertension

2010

Anti-hypertensive treatment cardiovascular risk continuous positive airway pressure treatment pathophysiology.Settore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma

2016

ArginineGenotypeGlycineAdrenergicSettore MED/10 - Malattie Dell'Apparato RespiratorioArginine03 medical and health sciences0302 clinical medicineGenotypemedicineImmunology and AllergyHumans030212 general & internal medicineReceptorAdrenergic beta-2 Receptor AgonistsAsthmaPolymorphism Geneticbusiness.industryHomozygoteAllergic asthmaasthmamedicine.disease030228 respiratory systemImmunologyReceptors Adrenergic beta-2business
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

Sleep Apnea, Sleepiness, and Driving Risk

2019

Obstructive sleep apnea is associated with excessive daytime sleepiness in about 50% of cases, and with increased risk of driving accidents. Treatment with continuous positive airway pressure effectively decreases such risk, but compliance with continuous positive airway pressure treatment is often suboptimal. According to the European Union Directive on driving risk, retention of a driving license in patients with obstructive sleep apnea requires assessment of sleepiness and adherence to continuous positive airway pressure treatment, but there remains uncertainty on the optimal methods to assess sleepiness on a large scale.

Automobile Drivingmedicine.medical_specialtySleepinessmedicine.medical_treatmentDriving riskExcessive daytime sleepinessSubjective sleepineSettore MED/10 - Malattie Dell'Apparato RespiratorioObjective sleepine03 medical and health sciencesSleep Apnea SyndromesSleep Apnea Syndrome0302 clinical medicineRisk FactorsCPAPEpidemiologymedicineHumansmedia_common.cataloged_instanceContinuous positive airway pressureWakefulnessEuropean unionobstructive sleep apneapathophysiologymedia_commonContinuous Positive Airway Pressurebusiness.industryRisk FactorWakefulneSleep apneaGeneral Medicinemedicine.diseasesubjective sleepinessrespiratory tract diseasesObstructive sleep apneaPsychiatry and Mental healthClinical PsychologyNeuropsychology and Physiological Psychology030228 respiratory systemEmergency medicineobjective sleepinessPatient ComplianceepidemiologyNeurology (clinical)medicine.symptombusinessOptimal methods030217 neurology & neurosurgeryHumanSleep Medicine Clinics
researchProduct

Is diet partly responsible for differences in COVID-19 death rates between and within countries?

2020

Abstract Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely use…

BLOOD-PRESSUREReviewAngiotensin-converting enzyme; Antioxidant; Coronavirus; Diet; Foodlaw.inventionDietary interventions0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases10183 Swiss Institute of Allergy and Asthma ResearchlawMedicine and Health SciencesImmunology and AllergyMedicine030212 general & internal medicine[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseaseseducation.field_of_studyMortality rate3. Good health[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases2723 Immunology and AllergyAntioxidantAngiotensin-converting enzymeAngiotensin-converting enzyme Antioxidant Coronavirus Diet FoodPulmonary and Respiratory Medicine2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)CoronaviruImmunologyPopulation610 Medicine & healthCOVID-19 ; Food ; Angiotensin-converting enzyme ; Diet ; Antioxidant ; CoronavirusSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesEnvironmental healthCOVID-19 ; population ; angiotensin-converting enzymeQuarantineeducation2403 ImmunologyANTIHYPERTENSIVE PEPTIDESbusiness.industryRC581-607GENEPOLYMORPHISMDietCoronavirus[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition030228 respiratory system2740 Pulmonary and Respiratory MedicineFoodImmunologic diseases. Allergybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionRegional differencesCoronavirus Infections
researchProduct

GOLD Staging System is Appropriate to Predict Mortality in Older People With Chronic Obstructive Pulmonary Disease

2018

Abstract Introduction In the new GOLD classification the reduction of FEV1, expressed as percentage of predicted value (FEV1PP), is considered an important prognostic factor. However, the use of FEV1PP may introduce bias, especially if based on equations derived from populations different from the one under study. We evaluated how well the GOLD classification stratifies the mortality risk when FEV1PP is based on an equation developed in the same population that gave rise to cases, externally developed equations, or as FEV1 divided by cubed height (FEV1/Ht3). Methods We studied 882 participants aged ≥65 years. Bronchial obstruction was defined using a fixed cut-off of 0.7 for FEV1/FVC. Predi…

BODE indexPulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesFEV1/FVC ratioFEV10302 clinical medicineElderlyInternal medicinemedicine030212 general & internal medicineGOLDeducationStaging systemCOPDeducation.field_of_studybusiness.industryChronic obstructive pulmonary diseaseHazard ratioGeneral Medicinerespiratory systemmedicine.diseaserespiratory tract diseases030228 respiratory systemQuartilebusiness
researchProduct

Occupational therapy, degree of disability and quality of life in COPD inpatients undergoing pulmonary rehabilitation programs

2010

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Broncopneumopatia cronica ostruttiva

2011

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Collagen I, III and IV content in airways and lung parenchyma of COPD patients

2010

BPCOSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct